MedTrace Logo

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

NCT04640545 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-05-13

No results posted yet for this study

Summary

A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors

Conditions

Interventions

DRUG

LBL-007

LBL-007 will be administered intravenously every two weeks (Q2W) .

DRUG

Toripalimab

Toripalimab Injection will be administered by intravenously (Q2W) .

DRUG

Axitinib Tablets

Axitinib Tablets On-demand administration

Sponsors & Collaborators

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Jun Guo, Prof · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2024-08-19
Completion
2024-08-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640545 on ClinicalTrials.gov